| Literature DB >> 25082101 |
Holly Kramer1, Jeffrey S Berns2, Michael J Choi3, Kevin Martin4, Michael V Rocco5.
Abstract
The benefits of and thresholds for 25-hydroxyvitamin D administration in individuals with chronic kidney disease (CKD) remain uncertain. In this report, NKF-KDOQI (National Kidney Foundation-Kidney Disease Outcomes Quality Initiative) endeavors to provide health care providers with the latest information on a controversial area in the management of CKD, the role for nutritional vitamin D. Although knowledge of the biological mechanisms of vitamin D for bone maintenance in individuals with all stages of CKD has expanded, no consensus currently exists within the medical community regarding methods for 25-hydroxyvitamin D supplementation or optimal 25-hydroxyvitamin D levels in individuals with CKD. Within this report, existing CKD guidelines are summarized and scrutinized and ongoing clinical trials are cited as sources for future guidance on the optimal management of vitamin D in CKD. Published by Elsevier Inc.Entities:
Keywords: 25-hydroxyvitamin D (25[OH]D); NKF-KDOQI (National Kidney Foundation–Kidney Disease Outcomes Quality Initiative); calcidiol; chronic kidney disease (CKD); clinical practice guidelines; vitamin D deficiency
Mesh：
Substances：
Year: 2014 PMID： 25082101 DOI： 10.1053/j.ajkd.2014.05.018
Source DB: PubMed Journal: Am J Kidney Dis ISSN： 0272-6386 Impact factor: 8.860